EUVIMEDEUVIMED entdecken
Open Access

Metabolic syndrome’s new therapy: Supplement the gut microbiome

Yong-Wei Xu, Jun Tian, Yan Song, Ba-Cui Zhang, Jing Wang

World Journal of Diabetes · 15.04.2024 · 15 (4) · 793-796

DOI: 10.4239/wjd.v15.i4.793 ↗

Kurz gefasst

Fachartikel in der Zeitschrift World Journal of Diabetes, online erschienen am 15.04.2024. Verfasst von Yong-Wei Xu und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Songjiang Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai 201600, China. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 16 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This letter to the editor discusses the publication on gut microbiome supplementation as therapy for metabolic syndrome. Gut microbiome dysbiosis disrupts intestinal bacterial homeostasis and is related to chronic inflammation, insulin resistance, cardiovascular diseases, type 2 diabetes mellitus, and obesity. Previous research has found that increasing the abundance of beneficial microbiota in the gut modulates metabolic syndrome by reducing chronic inflammation and insulin resistance. Prebiotics, probiotics, synbiotics, and postbiotics are often used as supplements to increase the number of beneficial microbes and thus the production of short-chain fatty acids, which have positive effects on the gut microbiome and metabolic syndrome. In this review article, the author summarizes the available supplements to increase the abundance of beneficial gut microbiota and reduce the abundance of harmful microbiota in patients with metabolic disorders. Our group is also researching the role of the gut microbiota in chronic liver disease. This article will be of great help to our research. At the end of the letter, the mechanism of the gut microbiota in chronic liver disease is discussed.

Schlagwörter

Stichwörter der Autor:innen

Chronic liver diseaseDiabetes mellitusGut microbiomeMetabolic syndromeShort-chain fatty acids

Autor:innen und Institutionen

  • Department of Gastroenterology, Songjiang Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai 201600, China.
  • Department of Gastroenterology, Songjiang Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai 201600, China. wangj0081@126.com.

Zitieren

APA

Xu, Y. W., Tian, J., Song, Y., Zhang, B. C., & Wang, J. (2024). Metabolic syndrome’s new therapy: Supplement the gut microbiome. World Journal of Diabetes, 15(4), 793-796. https://doi.org/10.4239/wjd.v15.i4.793

Vancouver

Xu YW, Tian J, Song Y, Zhang BC, Wang J. Metabolic syndrome’s new therapy: Supplement the gut microbiome. World Journal of Diabetes. 2024;15(4):793-796. doi:10.4239/wjd.v15.i4.793

BibTeX
@article{Xu2024,
  author = {Xu, Yong-Wei and Tian, Jun and Song, Yan and Zhang, Ba-Cui and Wang, Jing},
  title = {Metabolic syndrome’s new therapy: Supplement the gut microbiome},
  journal = {World Journal of Diabetes},
  year = {2024},
  volume = {15},
  number = {4},
  pages = {793--796},
  doi = {10.4239/wjd.v15.i4.793}
}
Kostenlos starten →